Company Quick10K Filing
Remedent
Price0.30 EPS0
Shares20 P/E3
MCap6 P/FCF11
Net Debt-0 EBIT2
TEV6 TEV/EBIT3
TTM 2019-09-30, in MM, except price, ratios
10-Q 2019-12-31 Filed 2020-02-14
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-K 2019-03-31 Filed 2019-06-28
10-Q 2018-12-31 Filed 2019-02-14
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-K 2018-03-31 Filed 2018-07-13
10-Q 2017-12-31 Filed 2018-02-14
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-14
10-K 2017-03-31 Filed 2017-06-29
10-Q 2016-12-31 Filed 2017-02-14
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-15
10-K 2016-03-31 Filed 2016-06-29
10-Q 2015-12-31 Filed 2016-02-16
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-14
10-K 2015-03-31 Filed 2015-06-29
10-Q 2014-12-31 Filed 2015-02-23
10-Q 2014-09-30 Filed 2014-11-19
10-Q 2014-06-30 Filed 2014-08-19
10-K 2014-03-31 Filed 2014-07-14
10-Q 2013-12-31 Filed 2014-02-14
10-Q 2013-09-30 Filed 2013-11-19
10-Q 2013-06-30 Filed 2013-08-14
10-K 2013-03-31 Filed 2013-07-15
10-Q 2012-06-30 Filed 2012-08-14
10-K 2012-03-31 Filed 2012-07-16
10-Q 2011-09-30 Filed 2011-11-21
10-Q 2011-06-30 Filed 2011-08-15
10-K 2011-03-31 Filed 2011-07-14
10-Q 2010-12-31 Filed 2011-02-14
10-Q 2010-09-30 Filed 2010-11-15
10-Q 2010-06-30 Filed 2010-08-16
10-K 2010-03-31 Filed 2010-07-13
10-Q 2009-12-31 Filed 2010-02-16

REMI 10Q Quarterly Report

Part I - Financial Information
Item 1.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. [Removed and Reserved]
Item 5. Other Information
Item 6. Exhibits
EX-31.1 v360718_ex31-1.htm
EX-31.2 v360718_ex31-2.htm
EX-32.1 v360718_ex32-1.htm
EX-32.2 v360718_ex32-2.htm

Remedent Earnings 2013-09-30

Balance SheetIncome StatementCash Flow
10.08.06.04.02.00.02012201420172020
Assets, Equity
10.07.95.93.81.8-0.32012201420172020
Rev, G Profit, Net Income
1.71.20.60.1-0.5-1.02012201420172020
Ops, Inv, Fin

10-Q 1 v360718_10q.htm FORM 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended September 30, 2013

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____.

 

Commission File No. 001-15975

 

REMEDENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   86-0837251

(State or Other Jurisdiction

Of Incorporation or Organization)

 

(I.R.S. Employer Identification

Number)

     
Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium   N/A
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code 011 32 9 241 58 80

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.

Yes x                                 No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x                                   No ¨

 

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
       
Non-accelerated filer ¨ Smaller reporting company x
(Do not check if a smaller reporting company)

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨                                 No x

 

As of November 19, 2013, there were 19,995,969 outstanding shares of the registrant’s common stock, includes 723,000 shares of treasury stock.

 

 
 

 

REMEDENT, INC.

 

FORM 10-Q INDEX

 

    Page Number
     
PART I – FINANCIAL INFORMATION    
Item 1.  Financial Statements    
Consolidated Balance Sheets as of September 30, 2013 (Unaudited) and March 31, 2013   1
Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2013 and September 30, 2012 (Unaudited)   2
Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2013 and September 30, 2012 (Unaudited)   3
Consolidated Statements of Cash Flows for the Three and Six Months Ended September 30, 2013 and September 30, 2012 (Unaudited)   4
Notes to Consolidated Financial Statements (Unaudited)   5
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations   16
Item 3.  Quantitative and Qualitative Disclosures About Market Risk   19
Item 4.  Controls and Procedures   19
     
PART II – OTHER INFORMATION    
Item 1.     Legal Proceedings   19
Item 1A.  Risk Factors   19
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds   19
Item 3.     Defaults Upon Senior Securities   19
Item 4.     [Removed and Reserved.]   19
Item 5.     Other Information   19
Item 6.     Exhibits   20
Signature Page   21

 

 
 

 

PART I – FINANCIAL INFORMATION

Item 1.

 

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   September 30, 
2013
   March 31, 2013 
ASSETS   (unaudited)       
CURRENT ASSETS:          
Cash and cash equivalents  $23,926   $64,504 
Accounts receivable, net of allowance for doubtful accounts of $5,099 at September 30, 2013 and $4,833 at March 31, 2013   761,078    947,971 
Inventories, net   984,675    991,807 
Prepaid expense   229,857    566,500 
Total current assets   1,999,536    2,570,782 
           
PROPERTY AND EQUIPMENT, NET   623,203    695,084 
OTHER ASSETS          
Investment in GlamSmile Asia Ltd   2,643,097    2,441,572 
Investment in MFI (Note 3)   787,339    787,339 
Patents, net   25,819    32,059 
Total assets  $6,078,994   $6,526,836 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
CURRENT LIABILITIES:          
Current portion, long term debt  $1,170,910   $1,214,266 
Line of Credit   671,963    836,355 
Accounts payable   1,028,072    971,814 
Accrued liabilities   416,152    737,064 
Deferred revenue   119,799    149,129 
Due to related parties        
Total current liabilities   3,406,896    3,908,628 
Long term debt less current portion   1,131,364    1,131,364 
Total liabilities   4,538,260    5,039,992 
           
EQUITY:          
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)        
Common stock, $0.001 par value; (50,000,000 shares authorized, 19,995,969 shares issued and outstanding at September 30, 2013 and March 31, 2013 respectively)   19,996    19,996 
Treasury stock, at cost; 723,000 shares outstanding at September 30, 2013 and March 31, 2013 respectively   (831,450)   (831,450)
Additional paid-in capital   24,906,269    24,906,269 
Accumulated deficit   (21,562,866)   (21,604,571)
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)   (1,106,077)   (1,118,262)
Obligation to issue shares (Note 3)   97,500    97,500 
Total Remedent, Inc. stockholders’ equity   1,523,372    1,469,482 
Non-controlling interest   17,362    17,362 
Total stockholders’ equity   1,540,734    1,486,844 
Total liabilities and equity  $6,078,994   $6,526,836 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1
 

 

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For the three months ended
September 30,
   For the six months ended
September 30,
 
   2013   2012   2013   2012 
                 
Net sales  $766,858   $434,025   $1,466,110   $848,559 
Cost of sales   254,131    259,890    517,151    514,445 
Gross profit   512,727    174,135    948,959    334,114 
Operating Expenses                    
Research and development   12,688    18,262    36,285    29,439 
Sales and marketing   156,622    173,745    346,003    346,299 
General and administrative   310,679    537,576    555,007    1,171,899 
Depreciation and amortization   59,760    83,523    119,303    173,117 
TOTAL OPERATING EXPENSES   539,749    813,106    1,056,598    1,720,754 
INCOME (LOSS) FROM OPERATIONS   (27,022)   (638,971)   (107,639)   (1,386,640)
OTHER INCOME (EXPENSES)                    
Gain on sale of Remedent OTC B.V.       521,159        521,159 
Equity income from investments   43,978    72,110    201,525    (6,915)
Interest expense   (27,257)   (46,570)   (55,875)   (97,256)
Interest income   2,940    4,462    10,175    6,272 
Other   (3,793)   (1,252)   (6,481)   (5,668)
TOTAL OTHER INCOME (EXPENSES)   15,868    549,909    149,344    417,592 
                     
NET (LOSS) INCOME  $(11,154)  $(89,062)  $41,705   $(969,048)
                     
 (LOSS) INCOME PER SHARE                    
Basic  $(0.00)  $(0.00)  $(0.00)  $(0.05)
Fully diluted  $(0.00)  $(0.00)  $(0.00)  $(0.05)
WEIGHTED AVERAGE SHARES OUTSTANDING                    
Basic   19,995,969    19,995,969    19,995,969    19,995,969 
Fully diluted   19,995,969    19,995,969    19,995,969    19,995,969 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2
 

 

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

 

   For the three months ended
September 30,
   For the six months ended
September 30,
 
   2013   2012   2013   2012 
Net (Loss  $(11,154)  $(89,062)  $41,705   $(969,048)
OTHER COMPREHENSIVE INCOME (LOSS):                    
Foreign currency translation adjustment   7,111    172,331    12,185    107,087 
COMPREHENSIVE INCOME (LOSS)  $(4,043)  $83,269   $53,890   $(861,961)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3
 

 

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For the six months ended
September 30,
 
   2013   2012 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
Net (loss) income  $41,705   $(969,048)
Adjustments to reconcile net income (loss) to net cash used by operating activities          
Gain on sale of Remedent OTC B.V.       (521,159)
Depreciation and amortization   119,303    173,117 
Inventory reserve   4,882    (5,468)
Allowance for doubtful accounts   266    (7,524)
Equity investment   (201,525)   6,915 
Changes in operating assets and liabilities:          
Accounts receivable   186,893    223,284 
Inventories   7,132    3,684 
Prepaid expenses   336,643    183,810 
Accounts payable   51,689    (64,429)
Accrued liabilities   (320,912)   (228,528)
Accrued and unpaid interest on debt       5,069 
Due to related parties       (16,571)
Deferred revenue   (29,330)   106,438 
Net cash provided by operating activities   196,746    (1,110,410)
CASH FLOWS FROM INVESTING ACTIVITIES          
Proceeds on sale of Remedent OTC B.V.       667,300 
Purchases of patent rights   (5,869)    
Purchases of equipment   (70,220)   (86,934)
Net cash used by investing activities   (76,089)   580,366 
CASH FLOWS FROM FINANCING ACTIVITIES          
Net (repayments of) capital leases and notes payable   (43,356)   (70,560)
(Repayments of) proceeds from line of credit   (164,392)   488,212 
Net cash provided by financing activities   (207,748)   417,652 
NET (DECREASE) INCREASE IN CASH   (87,091)   (112,392)
Effect of exchange rate changes on cash and cash equivalents   46,513    (66,199)
CASH AND CASH EQUIVALENTS, BEGINNING   64,504    203,584 
CASH AND CASH EQUIVALENTS, ENDING  $23,926   $24,993 
Supplemental Information:          
Interest paid  $30,806   $92,187 
Income taxes paid  $   $ 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4
 

 

REMEDENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1.DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION

 

The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental tooth whitening products which are distributed in Europe, Asia and the United States. The Company manufactures many of its products in Ghent, Belgium as well as outsourced manufacturing in its facility in Beijing, China and in France.  The Company distributes its products using both its own internal sales force and through the use of third party distributors.

 

In these notes, the terms “Remedent”, “Company”, “we”, “us” or “our” mean Remedent, Inc. and all of its subsidiaries, whose operations are included in these consolidated financial statements.

 

The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein.

 

As of September 30, 2013 the Company had working capital deficit of $1,407,362 and an accumulated deficit of $21,562,866. In the second half of the financial year ending March 31, 2013 management of the Company has taken measures to reduce general expenses and to increase sales prices which should have a positive impact on the results, the cash flow and the liquidity of the Company. Management is also convinced that, in case of necessity, important cash flows can be generated by the sale of investments of the Company. However, additional funding may be required in order to support the Company’s operations and the execution of its business plan. These risks, among others, are also discussed in ITEM 1A – Risk Factors in the Company’s annual report on Form 10-K filed on July 15, 2013 with the SEC. Despite these matters of emphasis, the financial statements have been prepared on a going concern basis.

 

The Company has conducted a subsequent events review through the date the financial statements were issued, and has concluded that there were no subsequent events requiring adjustments or additional disclosures to the Company's financial statements at September 30, 2013.

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended March 31, 2013, except as may be indicated below:

 

Organization and Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of: Remedent N.V. (incorporated in Belgium) located in Ghent , Belgium, Remedent Professional, Inc. and Remedent Professional Holdings, Inc. (both incorporated in California and inactive), Glamtech-USA, Inc. (a Delaware corporation acquired effective August 24, 2008), Remedent N.V.’s  51% owned subsidiary, GlamSmile Deutschland GmbH, a German private company located in Munich and Remedent N.V.’s 80 % owned subsidiary, GlamSmile Rome, an Italian private company located in Rome.

 

Remedent N.V.’s 29.4 % investment in Glamsmile Dental Technology Ltd., a Cayman Islands company (“Glamsmile Dental”) and its subsidiaries:

Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially 100 % owned subsidiary of Glamsmile Dental;

Beijing Glamsmile Technology Development Ltd., a 100 % owned subsidiary of GlamSmile Asia; its 80% owned subsidiary Beijing Glamsmile Trading Co., Ltd.; and its 98% owned subsidiary Beijing Glamsmile Dental Clinic Co., Ltd., including its 100% owned Shanghai Glamsmile Dental Clinic Co., Ltd., and its 50 % owned Whenzhou GlamSmile Dental Clinic Ltd.;

which are accounted for using the equity method after January 31, 2012 (see Note 3 – Long-term Investment)

 

Remedent, Inc. is a holding company with headquarters in Ghent, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception.

 

For all periods presented, all significant inter-company accounts and transactions have been eliminated in the consolidated financial statements and corporate administrative costs are not allocated to subsidiaries.

 

5
 

 

Interim Financial Information

 

The interim consolidated financial statements of Remedent, Inc. and Subsidiaries (the “Company”) are condensed and do not include some of the information necessary to obtain a complete understanding of the financial data. Management believes that all adjustments necessary for a fair presentation of results have been included in the unaudited consolidated financial statements for the interim periods presented. Operating results for the six months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ended March 31, 2014. Accordingly, your attention is directed to footnote disclosures found in the Annual Report on Form 10-K for the year ending March 31, 2013, and particularly to Note 2, which includes a summary of significant accounting policies.

 

Warranties

 

The Company typically warrants its products against defects in material and workmanship for a period of 24 months from shipment.

 

A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting periods is as follows:

 

   Six months
ended
September 30,
2013
   Year ended
March 31, 2013
 
Product warranty liability:          
Opening balance  $19,301   $20,019 
Accruals for product warranties issued in the period       (973)
Adjustments to liabilities for pre-existing warranties   1,062    255 
Ending liability  $20,363   $19,301 

 

Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $20,363 and $19,301 as of September 30, 2013 and March 31, 2013, respectively.

 

Computation of Earnings (Loss) per Share

 

Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.

  

On April 1, 2009, the Company adopted changes issued by the FASB to the calculation of earnings per share. These changes state that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method for all periods presented. The adoption of this change had no impact on the Company’s basic or diluted net loss per share because the Company has never issued any share-based awards that contain non-forfeitable rights.

 

At each of September 30, 2013 and March 31, 2013, the Company had 19,995,969, shares of common stock issued and outstanding.  At September 30, 2013 and March 31, 2013, the Company had Nil and 3,848,379 warrants outstanding respectively and 1,795,000 and 1,795,000 options outstanding respectively.  As of September 30, 2012, all outstanding warrants and options were excluded from the computation of earnings per share because their effect would have been anti-dilutive.  

 

Further, pursuant to ASC 260-10-50-1(c), if a fully diluted share calculation was computed for the three and six month periods ended September 30, 2013 and September 30, 2012 respectively, it would have excluded all warrants and all options respectively since the Company’s average share trading price during the three month and six month periods ended September 30, 2013 and September 30, 2012 were less than the exercise price of all other warrants and options.

 

Comprehensive income (loss) includes all changes in equity except those resulting from investments by owners and distributions to owners, including accumulated foreign currency translation, and unrealized gains or losses on marketable securities.

 

6
 

 

The Company’s only component of other comprehensive income is the accumulated foreign currency translation consisting of (loss) and gains of $12,185 and $107,087 for the Six months ended September 30, 2013 and 2012, respectively. These amounts have been recorded as a separate component of stockholders’ equity (deficit).

 

New Accounting Pronuncements

 

Recently Adopted

 

The below described accounting guidance has all been adopted by the Company effective April 1, 2013 and has not had a material impact upon the Company’s financial condition or results of operations.

 

In September 2011, the FASB issued new accounting guidance on testing goodwill for impairment. The primary objective of this accounting guidance is to reduce complexity and costs by allowing an entity to make a qualitative evaluation about the likelihood of goodwill impairment to determine whether it should calculate the fair value of a reporting unit. If, after assessing qualitative factors, an entity determines that it is not more likely than not (a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, then the two-step goodwill impairment test is unnecessary.

 

In December 2011, the FASB issued new accounting guidance on disclosures about offsetting assets and liabilities. The requirements for offsetting are different under U.S. GAAP and IFRS. Therefore, the objective of this accounting guidance is to facilitate comparison between financial statements prepared under U.S. GAAP and IFRS by enhancing disclosures of the effect or potential effect of netting arrangements on an entity’s financial position, including the effect or potential effect of rights of setoff associated with certain assets and liabilities.

 

In July 2012, the FASB issued guidance that simplifies how entities test indefinite-lived intangible assets for impairment, which improves consistency in impairment testing requirements among long-lived asset categories. ASU 2012-02 permits an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, ASU 2012-02 eliminates the requirement to perform quantitative impairment testing as outlined in the previously issued standards.

 

In February 2013, the FASB issued guidance that requires reporting of the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures that provide additional detail about these amounts. The amendments do not change the current requirements for reporting net income or other comprehensive income in the financial statements.

 

In January 2013, the FASB issued ASU No. 2013-01, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities, which clarifies which instruments and transactions are subject to the offsetting disclosure requirements originally established by ASU 2011-11. The new ASU addresses preparer concerns that the scope of the disclosure requirements under ASU 2011-11 was overly broad and imposed unintended costs that were not commensurate with estimated benefits to financial statement users. In choosing to narrow the scope of the offsetting disclosures, the Board determined that it could make them more operable and cost effective for preparers while still giving financial statement users sufficient information to analyze the most significant presentation differences between financial statements prepared in accordance with U.S. GAAP and those prepared under IFRSs

 

3.     LONG-TERM INVESTMENTS

 

REMEDENT OTC BV

 

In connection with the restructuring of the Company’s OTC business in December 2008, the Company controlled Remedent OTC BV until September 30, 2011 through its board representations. As agreed upon in the Voting Agreement, after September 30, 2011, the Company had one board representation and consequently no longer controlled its investment in Remedent OTC BV. As such, the financials of Remedent OTC BV are no longer included in the consolidated Financial Statements but accounted for through the equity method. No gain or loss was recorded on the deconsolidation. After September 30, 2011, the Company still owned 50% of Remedent OTC BV.

 

Effective July 13, 2012, and as amended February 7, 2013 the Company sold 100% of its interest in the share capital of Remedent OTC B.V., to an arm’s length party for the total sales price of €950,000 ( $667,300 (€ 500,000), (received during July 2012) and $600,570 (€450,000) was received in February 2013.

 

7
 

 

For the year ended March 31, 2013, the Company recorded an equity Loss of $(149,064) in “Other (expenses) income” for its portion of the net loss recorded by Remedent OTC B.V.

  

GLAMSMILE ASIA LTD.

 

Acquisition

 

Effective January 1, 2010 the Company acquired 50.98% of the issued and outstanding shares of Glamsmile Asia Ltd. (“Glamsmile Asia” or “Glamsmile”), a private Hong Kong company, with subsidiaries in Hong Kong and Mainland China, in exchange for the following consideration:

 

1.325,000 Euro (US$466,725).  As of March 31, 2011 the full amount was paid.
2.250,000 shares of common stock to be issued during the fiscal year ended March 31, 2011 ($97,500 was recorded as an obligation to issue shares as at March 31, 2010).  The parties have agreed that the shares will be issued during fiscal year ended March 31, 2013.
3.100,000 options on closing (issued);
4.100,000 options per opened store at closing (issued);
5.100,000 options for each additional store opened before the end of 2011 at the price of the opening date of the store;
6.Assumption of Glamsmile’s January 1, 2010 deficit of $73,302.; and
7.Repayment of the founding shareholder’s original advances in the amount of $196,599.  The balance of $196,599, recorded as due to related parties at March 31, 2010, is unsecured, non-interest bearing and has no specific terms of repayment other than it will be paid out of revenues from Glamsmile, as working capital allows.  During the year ended March 31, 2011 a total of $101,245 was paid to the founding shareholder, leaving a balance due of $95,354 on June 27, 2011. As at March 31, 2012 the full amount was paid.

 

All options reside under the Company’s option plan and are five year options.

 

Also pursuant to the agreement, the Company granted irrevocable right to Glamsmile Asia to use the Glamsmile trademark in Greater China.

 

The Company acquired a 50.98% interest in GlamSmile Asia Ltd. (“GlamSmile Asia”) in order to obtain a platform in the Chinese Market to expand and introduce our GlamSmile Asia concept into the Chinese Market. In order to sell into the Chinese Market, an approval by Chinese Authorities is required, in the form of licenses. As GlamSmile Asia was already the owner of such licenses prior to the acquisition, this was an important advantage. We obtained control of GlamSmile Asia through the acquisition of the 50.98% interest and the appointment of our CEO as a Board member of GlamSmile Asia.

 

Deconsolidation

 

On January 28, 2012, the Company entered into a Preference A Shares and Preference A-1 Shares Purchase Agreement (“Share Purchase Agreement”) with Glamsmile Dental Technology Ltd., a Cayman Islands company and a subsidiary of the Company (“Glamsmile Dental”), Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially owned subsidiary of Glamsmile Dental, Beijing Glamsmile Technology Development Ltd., Beijing Glamsmile Trading Co., Ltd., Beijing Glamsmile Dental Clinic Co., Ltd., and Shanghai Glamsmile Dental Clinic Co., Ltd., Gallant Network Limited, a shareholder of Glamsmile Dental (“Gallant”), and IDG-Accel China Growth Fund III L.P. (“IDG Growth”), IDG-Accel China III Investors L.P.(“IDG Investors”) and Crown Link Group Limited (“Crown”)(“IDG Growth, IDG Investors and Crown collectively referred to as the “Investors”), pursuant to which the Investors agreed to (i) purchase from the Company an aggregate of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental, which represents all of the issued and outstanding Preference A-1 Shares of Glamsmile Dental, for an aggregate purchase price of $2,000,000, and (ii) purchase from Glamsmile Dental an aggregate of 5,000,000 shares of Preference A Shares for an aggregate purchase price of $5,000,000.

 

Under the terms of the Share Purchase Agreement, the Company agreed (a) to indemnify the Investors and their respective affiliates for losses arising out of a breach, or inaccuracy or misrepresentation in any representation or warranty made by the Company or a breach or violation of a covenant or agreement made by the Company for up to $1,500,000, and (b) to transfer 500,000 shares of Glamsmile Dental owned by the Company to the Investors in the event of breach of certain covenants by the Company. In connection with the Share Purchase Agreement, the Company also agreed to enter into an Investor’s Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement with the parties.

 

In addition, in connection with the contemplated transactions in the Share Purchase Agreement on January 20, 2012, the Company entered into a Distribution, License and Manufacturing Agreement with Glamsmile Dental pursuant to which the Company appointed Glamsmile Dental as the exclusive distributor and licensee of Glamsmile Veneer Products bearing the “Glamsmile” name and mark in the B2C Market in the People’s Republic of China (including Hong Kong and Macau) and Republic of China (Taiwan) and granted related manufacturing rights and licenses in exchange for the original issuance of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental and $250,000 (the receipt of which was acknowledged as an offset to payment of certain invoices of Glamsmile (Asia) Limited).

 

8
 

 

On February 10, 2012, the sale of the Preference A-1 Shares and the Preference A Shares was completed. As a result of the closing, the equity ownership of Glamsmile Dental, on an as converted basis, is as follows: 31.4% by the Investors, 39.2 % by Gallant, and 29.4% by the Company. Mr. De Vreese, our chairman, will remain as a director of Glamsmile Dental along with Mr. David Lok, who is the Chief Executive Officer and director of Glamsmile Dental and principal of Gallant. The Investors have a right to appoint one director of Glamsmile Dental, and accordingly the Board of Directors of Glamsmile Dental will consist of Mr. De Vreese, Mr. Lok and a director appointed by the Investors.

 

In conjunction with the transaction and resulting deconsolidation of Glamsmile Dental, the Company recorded a gain of $1,470,776, calculated as follows:

 

Consideration received  $2,000,000 
Fair value of 29.4% interest   2,055,884 
Carrying value of non-controlling interest   1,117,938 
Less: carrying value of former subsidiary’s net assets   (2,002,329)
Goodwill   (699,635)
Investment China & Hong Kong   (1,082)
Rescission agreement  Excelsior  (Note 11)   (1,000,000)
   $1,470,776 

 

For the six month periods ended September 30, 2013 and September 30, 2012 the Company recorded equity income of $201,525 and $142,149 respectively as “Other (expenses) income” for its portion of the net income recorded by GlamSmile Dental Technology Ltd.

 

MEDICAL FRANCHISES & INVESTMENTS

 

Effective March 31, 2013, the Company acquired 6.12 % of the issued and outstanding shares of Medical Franchises & Investments N.V., a Belgium corporation ("MFI NV") in exchange for a cash prepayment of $314,778 that was made during the fiscal year ended March 31, 2012. The Company’s investment in 70,334 shares of MFI NV has been recorded at the fair value of $787,339 which is the quoted market price of approximately USD $11.19 (€8.70) per share. Because the investment is being recognized as an available-for-sale investment, an unrecognized gain of $472,561 has been recorded in accumulated other comprehensive income. Future unrealized gains and losses on the investment in MFI will also be recognized in other comprehensive income until realized.

 

Per ASC-320-10-25-1, investments in debt and equity securities that have readily determinable fair values and are not classified as trading or held-to-maturity securities, are classified as available-for-sale securities.

 

MFI NV has been founded to market an advance in dental technology which has the potential to replace the process of making mechanical impressions of teeth and bite structures with a digital/optical scan.

 

4.SHORT TERM LOAN

 

Effective December 3, 2012, the Company entered into a Loan Agreement (the “Loan Agreement”) with BNP Paribas Fortis Bank, a Belgian Bank, pursuant to which the Company borrowed $132,820 (€100.000). The loan bears interest of 3.68 % per annum and is repayable in 24 equal monthly installments of € 4,331 ($5,573 at the closing rate of March 31, 2013). No additional guaranties (see note 13- secured debt agreements (2)) were required.

 

As of September 30, 2013 the Company has recorded $33,947 as a current liability and the balance of $49,378 as long term (March 31, 2013, $63,728 and $49,378 respectively).

 

5.CONCENTRATION OF RISK

 

Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable.

 

9
 

 

Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas.  At September 30, 2013, five customers accounted for 62.52% of the Company’s trade accounts receivables, and one customer accounted for 44.62%.   The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable.

 

Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations.  For the six months ended September 30, 2013 the Company had five suppliers who accounted for 23.08% of gross purchases. For the Six months ended September 30, 2012 the Company had five suppliers who accounted for 27.89% of gross purchases.

 

Revenues —  For the six months ended September 30, 2013 the Company had five customers that accounted for 87.23% of total revenues. For the six months ended September 30, 2012 the Company had five customers that accounted for 72.03% of total revenues.

 

6.ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

 

The Company’s accounts receivable at period end were as follows:

 

   September 30,
2013
   March 31, 2013 
Accounts receivable, gross  $766,177   $952,804 
Less: allowance for doubtful accounts   (5,099)   (4,833)
Accounts receivable, net  $761,078   $947,971 

 

7.INVENTORIES

 

Inventories at period end are stated at the lower of cost (first-in, first-out) or net realizable value and consisted of the following:

 

   September 30,
2013
   March 31, 2013 
Raw materials  $33,356   $38,452 
Components   223,367    214,723 
Finished goods   821,558    827,356 
    1,078,281    1,080,531 
Less: reserve for obsolescence   (93,606)   (88,724)
Net inventory  $984,675   $991,807 

 

8.PREPAID EXPENSES

 

Prepaid expenses are summarized as follows:

 

   September 30,
2013
   March 31, 2013 
Prepaid materials and components  $47,155   $196,876 
Prepaid Consulting   12,892    73,854 
VAT payments in excess of VAT receipts   19,972    41,241 
Prepaid trade show expenses       4,632 
Prepaid rent   126,926    129,957 
Other   22,912    119,940 
   $229,857   $566,500 

 

10
 

 

9.PROPERTY AND EQUIPMENT

 

Property and equipment are summarized as follows:

 

   September 30,
2013
   March 31, 2013 
Furniture and Fixtures  $599,950   $596,471 
Machinery and Equipment   1,650,260    1,619,770 
    2,250,210    2,216,241 
Accumulated depreciation   (1,627,007)   (1,521,157)
Property & equipment, net  $623,203   $695,084 

 

10.LINE OF CREDIT

 

The Company has a mixed-use line of credit facility with BNP Paribas Fortis Bank, a Belgian bank (the “Facility”). The Facility is secured by a first lien on the assets of Remedent N.V. and by personal guarantee of the Company’s CEO.

 

Effective September 3, 2013 we have agreed to repay our line of credit of € 495.000 (US $671,963) in 10 installments of € 49.500 (US $67,196) + an interest of 3,6 % per year commencing November 1, 2013, with the last payment due on August 1, 2014.

 

11.LONG TERM DEBT

 

Capital Lease Agreements:

 

On January 15, 2010, the Company entered into a capital lease agreement over a 5 year period for veneer manufacturing equipment totaling €251,903 (US $341,958).

 

The lease requires a monthly payment of principal and interest at 9.72% and provide for a buyout at the conclusion of the lease terms of 4% of the original value of the contract.

 

The net book value as of September 30, 2013 and March 31, 2013 of the equipment subject to the foregoing lease was $121,412 and $160,056 respectively.

 

The following is a schedule by years of future minimum lease payments under capital lease together with the present value of the net minimum lease payments as of March 31, 2013:

 

Year ending March 31:  $ 
     
2014   41,409 
2015   83,509 
2016    
Later years    
Total minimum lease payments   124,918 
Less: Amount representing estimated executory costs (such as taxes, maintenance, and insurance), including profit thereon, included in total minimum lease payments    
Net minimum lease payments   124,918 
Less: Amount representing interest (*)   3,506 
Present value of minimum lease payments (**)  $121,412 

 

*  Amount necessary to reduce net minimum lease payments to present value calculated at the Company’s incremental borrowing rate at the inception of the leases.

** Reflected in the balance sheet as current and non-current obligations under capital leases of $39,426 and $81,986 respectively.

 

11
 

 

Secured Debt Agreements (1)

 

On June 3, 2011, the Company obtained a loan in the principal amount of $1,000,000 (the “Loan”) from an unrelated private company, Excelsior Medical (HK) (“EM”). In connection with the Loan, the Company issued a promissory note, with a simple interest rate of 5% per annum, secured by certain assets of the Company (the “Note”). The maturity date of the Loan is June 3, 2014. Interest of $50,000 per annum is payable in cash on an annual basis.

 

Effective as of January 11, 2012, the Company entered into a Rescission Agreement with EM and Asia Best Healthcare Co., Ltd. Under the Rescission Agreement, the Company agreed to repay a total of $1,000,000 received under the Distribution Agreement, plus a simple interest rate of 5%, beginning on June 30, 2012, according to the following payment schedule: (i) $250,000 to be paid no later than June 30 , 2012, (ii) $250,000 plus interest on June 30, 2012, (iii) $250,000 plus interest on December 31, 2012, and (iv) $250,000 plus interest on June 30, 2013. The Company also agreed to secure such obligations owed to EM with certain collateral of the Company. During the period ended December 31, 2012 a partial payment of $20,000 in interest has been made. The Company is currently in the process of re-negotiating the terms of repayment.

 

Secured Debt Agreements (2)

 

On December 3, 2012, the Company obtained a loan in the principal amount of € 100,000 (the “Loan”) from BNP Paribas Fortis bank, to be repaid over the next 24 months. The loan is secured by a lien on the assets of Remedent N.V. as already granted for the use of our existing Credit Line Facility. The maturity date of the Loan is January 2, 2015 at an Interest of 3.68% to be repaid in monthly installments of € 4,331 ($5,879).

 

12.DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS

 

Transactions with related parties not disclosed elsewhere in these financial statements consisted of the following:

 

Compensation:

 

During the six month periods ended September 30, 2013 and 2012 respectively, the Company incurred $117,673 and $272,321 respectively, as compensation for all directors and officers.

 

All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties and in management’s opinion reflects arms length consideration payable for similar services or transfers.

 

13.ACCRUED LIABILITIES

 

Accrued liabilities are summarized as follows:

 

   September 30,
2013
   March 31, 2013 
Accrued employee benefit taxes and payroll  $259,817   $397,666 
Accrued travel   6,788    9,650 
Accrued audit and tax preparation fees   18,502    14,264 
Reserve for warranty costs   20,363    19,301 
Advances received on account       11,823 
Accrued advertising   10,693    9,864 
Accrued interest       12,578 
Accrued consulting fees   1,500    2,500 
Other accrued expenses   98,489    259,418 
   $416,152   $737,064 

 

12
 

 

14.EQUITY COMPENSATION PLANS

 

As of September 30, 2013, the Company had three equity compensation plans approved by its stockholders (1) the 2001 Incentive and Non-statutory Stock Option Plan (the “2001 Plan”), (2) the 2004 Incentive and Non-statutory Stock Option Plan (the “2004 Plan”); and (3) the 2007 Equity Incentive Plan (the “2007 Plan”). The Company’s stockholders approved the 2001 Plan reserving 250,000 shares of common stock of the Company pursuant to an Information Statement on Schedule 14C filed with the Commission on August 15, 2001. In addition, the Company’s stockholders approved the 2004 Plan reserving 800,000 shares of common stock of the Company pursuant to an Information Statement on Schedule 14C filed with the Commission on May 9, 2005.  Finally, the Company’s stockholders approved the 2007 Plan reserving 1,000,000 shares of common stock of the Company pursuant to a Definitive Proxy Statement on Schedule 14A filed with the Commission on October 2, 2007.

 

In addition to the equity compensation plans approved by the Company’s stockholders, the Company has issued options and warrants to individuals pursuant to individual compensation plans not approved by our stockholders.  These options and warrants have been issued in exchange for services or goods received by the Company.

 

The following table provides aggregate information as of September 30, 2013 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance.

 

   2001 Plan   2004 Plan   2007 Plan   Other 
   Outstanding
Options
   Weighted
Average
Exercise
Price
   Outstanding
Options
   Weighted
Average
Exercise
Price
   Outstanding
Options
   Weighted
Average
Exercise
Price
   Outstanding
Options
   Weighted
Average
Exercise
Price
 
                                 
Options outstanding, March 31, 2013   12,500    1.19    432,500    0.96    1,000,000    1.21    350,000    .97 
Options outstanding andexercisable September 30, 2013   12,500    1.19    432,500    0.96    1,000,000    1.21    350,000    .97 
Exercise price range  $2.00         $0.50 - $2.46         $0.50 - $1.75         $.39 - 1.75      
Weighted average remaining life   0.5 years         4.5  years         4.62 years         3.1 years      

  

A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows:

 

Plan Category  Number of
securities to
be
issued upon
exercise of
of
outstanding
options,
warrants
and rights
   Weighted-average
exercise price of
outstanding
options
warrants and
rights
   Number of
securities
remaining
available for
future
issuance
under
equity
compensation
plans
(excluding
securities
reflected
in column (a))
 
Equity Compensation Plans approved by security holders   1,445,000   $1.17    605,000 
Equity Compensation Plans not approved by security holders   820,000   $.97    NA 
Total   2,265,000   $1.10    605,000 

 

13
 

 

For the three month periods ended September 30, 2013 and September 30, 2012 the Company recognized $Nil (2012 — $Nil) in stock based compensation expense in the consolidated statement of operations.  No stock options were granted or cancelled/expired in the three month periods ended September 30, 2013 and September 30, 2012.

 

15.COMMON STOCK WARRANTS AND OTHER OPTIONS

 

As of September 30, 2013 and March 31, 2013, the Company had warrants to purchase the Company’s common stock outstanding that were not granted under shareholder approved equity compensation plans as follows:

 

   Outstanding
Warrants
   Weighted
Average
Exercise
Price
 
Warrants outstanding and exercisable March 31, 2013   3,738,379   $1.40 
Expired in the period   (3,738,379)     
Warrants outstanding and exercisable September 30, 2013         

 

16.SEGMENT INFORMATION

 

The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., GlamSmile Deutschland GmbH and GlamSmile Rome SRL in Europe.

 

17.COMMITMENTS

 

Real Estate Lease:

 

The Company leases an office facility of 5,187 square feet in Gent, Belgium from an unrelated party pursuant to a nine year lease commencing September 1, 2008 at a base rent of €5,713 per month for the total location ($7,755 per month at September 30, 2013).

 

Additionally, the Company leases an office facility of 635 square feet in Brussels, Belgium from an unrelated party pursuant to a nine year lease commencing July 1, 2012 at a base rent of € 969 per month for the total location ($1,315 per month at September 30, 2013).

 

Finally, the Company leases an office facility of 1,991 square feet in Rome, Italy to support the sales and marketing division of our veneer business, from an unrelated party pursuant to a six year lease commencing July 1, 2011, at a base rent of €6,500 per month for the total location ($8,824 per month at September 30, 2013).

 

Real Estate Lease and All Other Leased Equipment:

 

Minimum monthly lease payments for real estate, and all other leased equipment are as follows based upon the conversion rate for the (Euro) at September 30, 2013:

 

March 31, 2014   217,106 
March 31, 2015   383,975 
March 31, 2016   288,251 
March 31, 2017   248,325 
After five years   142,609 
Total:  $1,280,266 

 

18.FINANCIAL INSTRUMENTS

 

The FASB ASC topic 820 on fair value measurement and disclosures establishes three levels of inputs that may be used to measure fair value: quoted prices in active markets for identical assets or liabilities (referred to as Level 1), observable inputs other than Level 1 that are observable for the asset or liability either directly or indirectly (referred to as Level 2), and unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities (referred to as Level 3).

 

14
 

 

The carrying values and fair values of our financial instruments are as follows:

 

       September 30, 2013   March 31, 2013 
       Carrying   Fair   Carrying   Fair 
   Level   Value   Value   value   value 
Cash   1   $23,926   $23,926   $64,504   $64,504 
Accounts receivable   2   $761,078   $761,078   $947,971   $947,971 
Long Term investment and advance - GlamSmile Dental Technology Asia   2   $2,643,097   $2,643,097   $2,441,572   $2,441,572 
Long term investments and advances MFI   2   $787,339   $787,339   $787,339   $787,339 
Line of credit   2   $671,963   $671,963   $836,355   $836,355 
Short term debt   2   $1,170,910   $1,170,910   $1,214,266   $1,214,266 
Deferred revenue   2   $119,799   $119,799   $149,129   $149,129 
Accounts payable   2   $1,028,072   $1,028,072   $971,813   $971,813 
Accrued liabilities   2   $416,152   $416,152   $737,064   $737,064 
Long term debt   2   $1,131,364   $1,131,364   $1,131,364   $1,131,364 

 

The following method was used to estimate the fair values of our financial instruments:

 

The carrying amount of level 1 and level 2 financial instruments approximates fair value because of the short maturity of the instruments.

 

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation.

 

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the three month periods ended September 30, 2013 or September 30, 2012. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following table provides a reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 3):

 

   Six month period ended
September 30,
2013
 
Long term investments and advances:     
Beginning balance  $2,441,572 
Gains (losses) included in net loss   201,525 
Transfers in (out of level 3)    
      
Ending balance  $2,643,097 

 

15
 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward Looking Statements

 

The discussion contained herein is for the three months ended September 30, 2013 and September 30, 2012. The following discussion should be read in conjunction with the Company’s consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013.  In addition to historical information, this section contains “forward-looking” statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors.  Factors that could cause or contribute to any differences are discussed in “Risk Factors” and elsewhere in the Company’s annual report on Form 10-K filed on July 15, 2013 with the Securities and Exchange Commission.  Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013. The information contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2013 is not a complete description of the Company’s business or the risks associated with an investment in the Company’s common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-Q and in the Company’s other filings with the Securities and Exchange Commission.

 

Overview

 

We specialize in the research, development, and manufacturing of oral care and cosmetic dentistry products.  We are one of the leading manufacturers of cosmetic dentistry products in Europe.  Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we design, develop, manufacture and distribute our cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia and the United States.    We distribute our products using both our own internal sales force and through the use of third party distributors.

 

Result of Operations

 

Comparative detail of results as a percentage of sales, is as follows:

 

   For the three months ended
September 30,
   For the six months ended
September 30,
 
   2013   2012   2013   2012 
                 
NET SALES   100.00%   100.00%   100.00%   100.00%
COST OF SALES   33.14%   59.88%   35.27%   60.63%
GROSS PROFIT   66.86%   40.12%   64.73%   39.37%
OPERATING EXPENSES                    
Research and development   1.65%   4.21%   2.47%   3.47%
Sales and marketing   20.42%   40.03%   23.60%   40.81%
General and administrative   40.51%   123.86%   37.86%   138.10%
Depreciation and amortization   7.79%   19.24%   8.14%   20.40%
TOTAL OPERATING EXPENSES   70.37%   187.34%   72.07%   202.78%
INCOME (LOSS) FROM OPERATIONS   (3.51)%   (147.22)%   (7.34)%   (163.41)%
Other income (expense)   2.08%   126.70%   10.19%   49.21%
NET INCOME (LOSS)   (1.43)%   (20.52)%   2.85%   (114.20)%

 

16
 

 

Net Sales

  

Net sales increased by approximately 76.7% to $766,858 for the three months ended September 30, 2013 as compared to $434,025 for the three months ended September 30, 2012.  The increase in sales is primarily due to increased sales of veneers and veneer related products.

 

Net sales increased by approximately 72.8% to $1,466,110 for the six months ended September 30, 2013 as compared to $848,559 for the six months ended September 30, 2012.  The increase in sales is primarily due to increased sales of veneers and the sales results of our River 8 related products.

 

Cost of Sales

 

Cost of sales decreased approximately 2.2% to $254,131 for the three months ended September 30, 2013 as compared to $259,890 for the three months ended September 30, 2012.   Cost of sales, as a percentage of net sales, has decreased to 33.14 % in the quarter ended September 30, 2013 as compared to 59.88 % in the quarter ended September 30, 2012. The decrease in cost of sales and cost of sales as a percentage of sales is primarily because of new production strategies which have enabled us to reduce our production costs.

 

Cost of sales increased approximately .5% to $517,151 for the six months ended September 30, 2013 as compared to $514,445 for the six months ended September 30, 2012.  The small increase of cost of sales is because of increased sales, totally compensated by increased efficiencies in production as explained above.

 

Gross Profit

 

Our gross profit increased by $338,592 or 194.4% to $512,727 for the three months ended September 30, 2013 as compared to $174,135 for the three months ended September 30, 2012. Our gross profit as a percentage of sales increased to 66.86% in the three months ended September 30, 2013 as compared to 40.12% for the three months ended September 30, 2012. Our gross profit has increased because of increased sales, improved pricing of our veneers, and improved production processes.

 

Our gross profit increased by $614,845 or 184%, to $948,959 for the six months ended September 30, 2013 as compared to $334,114 for the six months ended September 30, 2012 primarily because of increased sales and increased pricing of our veneers and improved production process.

 

Operating Expenses

 

Research and Development.  Our research and development expenses decreased by $5,574 to $12,688 for the three months ended September 30, 2013 as compared to $18,262 for the three months ended September 30, 2012, a decrease of 30.5%. The decrease in our research and development costs was primarily because of nonrecurring costs with respect to the “Smile me Mirror”concept which is in its final phase before being launched.

 

Our research and development costs increased by $6,846 or 23.3% to $36,285 for the six months ended September 30, 2013 as compared to $29,439 for the six months ended September 30, 2012 primarily because of our ongoing efforts with respect to a new concept “Smile me Mirror” that is scheduled to be launched at the end of the current calendar year.

 

Sales and marketing costs. Our sales and marketing costs for the three months ended September 30, 2013 and 2012 were $156,622 and $173,745 respectively, representing a decrease of $17,123 or 9.9%.  The decrease is largely due to our internal reorganization which took place at the yearend of 2012.

 

Our sales and marketing costs decreased by $296 or .1% to $346,003 for the six months ended September 30, 2013 as compared to $346,299 for the six months ended September 30, 2012.

 

The stability is the result of ongoing marketing efforts, compensated by the full effect of our internal reorganisation at yearend 2012.

 

General and administrative costs. Our general and administrative costs for the three months ended September 30, 2013 and 2012 were $310,679 and $537,576 respectively, representing a decrease of $226,897, or 42.2%. Our general and administrative costs for the six months ended September 30, 2013 and 2012 were $555,007 and $1,171,899 respectively, representing a decrease of $616,892 or 52.6%.  The decrease in general and administrative costs as compared to the six months ended September 30, 2012 is a result of the reorganization and downsizing of our European Divisions by optimizing our processes thereby allowing us to reduce overall costs.

 

Depreciation and amortization.   Our depreciation and amortization decreased $23,763 or 28.5% to $59,760 for the three months ended September 30, 2013 as compared to $83,523 for the three months ended September 30, 2012.   The decrease is largely because previous investments in machinery and equipment are now fully amortized. Our depreciation and amortization decreased $53,814 or 31.1%, to $119,303 for the six months ended September 30, 2013 as compared to $173,117 for the six months ended September 30, 2012.   The decrease is because previous investments in machinery and equipment are now fully amortized.

 

17
 

 

Other income (expense).   Our net other income (expense) was $15,868 for the three months ended September 30, 2013 as compared to $549,909 for the three months ended September 30, 2012, a decrease in other income of $534,041.    The decrease in other income was primarily because we recognized a one-time gain of $521,159 on the sale of our OTC division in the 2012 comparative period.

 

Our net other income (expense) was $149,344 for the six months ended September 30, 2013 as compared to $417,592 for the six months ended September 30, 2012, a decrease in other income of $268,248.   The decrease in other income was primarily because of the one-time gain on the sale of our OTC division in the 2012 comparative period.

 

Internal and External Sources of Liquidity

 

As of September 30, 2013, we had current assets of $1,999,536 compared to $2,570,782 at March 31, 2013. This decrease of $571,246 was primarily due to a decrease in prepaid expenses of $336,643, a decrease in accounts receivable of $186,893 and a decrease in cash of $40,578. Current liabilities at September 30, 2013 were $3,406,898 as compared to $3,908,628 at March 31, 2013. The decrease in current liabilities of $501,730 was primarily as a result of decreases in our accrued liabilities, line of credit, current portion of long-term debt and deferred revenue in the amounts of $320,912, $164,392, $43,356 and $29,330 respectively, offset by an increase in accounts payable of $54,384.

 

As of September 30, 2013, we had cash of $23,926. We anticipate that we will need to raise additional funds to satisfy our working capital requirements and implement our business strategy to expand our direct to consumer business model. We intend to continue to look for opportunities to expand the number of GlamSmile Studios in Europe.  We will continue to review our expected cash requirements, make all efforts to collect any aged receivables, and take appropriate cost reduction measures to ensure that we have sufficient working capital to fund our operations. In the event additional needs for cash arise, we may seek to raise additional funds from a combination of sources including issuance of debt or equity securities. Additional financing may not be available on terms favorable to us, or at all. Any additional financing activity could be dilutive to our current stockholders. If adequate funds are not available or are not available on acceptable terms, our ability to take advantage of unanticipated opportunities or respond to competitive pressures could be limited.

 

Cash and Cash equivalents

 

Our balance sheet at September 30, 2013 reflects cash of $23,926 as compared to $64,504 as of March 31, 2013, a decrease of $40,578.

 

Operations

 

Net cash provided by (used by) operations was $196,746 for the six months ended September 30, 2013 as compared to net cash used by operations of $(1,117,325) for the six months ended September 30, 2012. The increase of $1,307,156 in net cash provided by operations for the six months ended September 30, 2013 as compared to the six months ended September 30, 2012 is primarily because we recognized net income of $41,798 as opposed to a net loss of $(969,048).

 

Investing activities

 

Net cash used in investing activities totaled $76,089 for the six months ended September 30, 2013 as compared to net cash provided by investing activities of $580,366 for the six months ended September 30, 2013. Cash used in the six months ended September 30, 2013 and 2012 was primarily for investing in equipment. We received a total of $667,300 in the comparative period as proceeds from the sale of our OTC division.

 

Financing activities

 

Net cash (used)/provided by financing activities totaled $(207,748) for the six months ended September 30, 2013, as compared to $417,652 for the six months ended September 30, 2012.  The decrease in the net cash provided by financing activities in the six month period ended September 30, 2013 of $625,400 was primarily as a result of our decrease in our line of credit.

 

During the six months ended September 30, 2013 and September 30, 2012, we recognized an increase/ (decrease) in cash and cash equivalents of $46,513 and $(66,199), respectively, from the effect of exchange rates between the Euro and the US Dollar.

 

Off-Balance Sheet Arrangements

 

At September 30, 2013, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

 

18
 

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

 

Not Applicable.

 

Item 4.  Controls and Procedures

  

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the required time periods and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.  In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objective, and management is required to exercise its judgment in evaluating the cost-benefit relationship of possible controls and procedures..

 

Management conducted an evaluation, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2013.  Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2013.

 

Changes in Internal Control Over Financial Reporting

 

There have been no material changes in our  internal controls over financial reporting identified in connection with the evaluation of disclosure controls and procedures discussed above that occurred during the quarter ended September 30, 2013 or subsequent to that date that have materially affected, or are reasonably likely to materially affect, our  internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1.  Legal Proceedings

 

To the best knowledge of management, there are no material legal proceedings pending against the Company.

 

Item 1A.  Risk Factors

 

Not Applicable.

 

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

 

None. 

 

Item 3.  Defaults Upon Senior Securities

 

None.

 

Item 4.  [Removed and Reserved]

 

Item 5.  Other Information

 

None.

 

19
 

 

Item 6.  Exhibits

 

EXHIBIT INDEX

 

Exhibit No   Description
     
31.1*   Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act
     
31.2*   Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act
     
32.1*   Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act
     
32.2*   Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act
     
101.INS**   XBRL Instance Document
     
101.SCH**   XBRL Taxonomy Extension Schema
     
101.CAL**   XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF**   XBRL Taxonomy Extension Definition Linkbase
     
101.LAB**   XBRL Taxonomy Extension Label Linkbase
     
101.PRE**   XBRL Taxonomy Extension Presentation Linkbase

 

 

 

* Filed herewith

 

**XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

20
 

  

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  REMEDENT, INC.
   
Date:    November  19, 2013 By: /s/ Guy De Vreese
    Name:  Guy De Vreese
   

Title:    Chief Executive Officer

     (Principal Executive Officer)

   
Date:    November  19, 2013 By: /s/ Philippe Van Acker
    Name:  Philippe Van Acker
   

Title:    Chief Financial Officer

     (Principal Financial and Accounting Officer)

 

21